ImmunoCellular Therapeutics, Ltd Set to be Added to Russell 3000, Russell Global and Russell Microcap Indexes

Published: Jun 18, 2012

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”)(NYSE MKT: IMUC), a clinical stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, today announced that it is scheduled to join the U.S. broad-market Russell 3000®, Global and Microcap Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, 2012, according to a preliminary list of additions posted on June 8 on the Russell website at

Back to news